Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 472 results found since Jan 2013.
Key elements in hypersensitivity reactions to chemotherapy: experience with rapid drug desensitization in gynaecological cancer in a tertiary hospital
Eur Ann Allergy Clin Immunol. 2021 May 4. doi: 10.23822/EurAnnACI.1764-1489.207. Online ahead of print.ABSTRACTRapid drug desensitization (RDD) is a procedure performed when no alternative drug is considered equally effective. The aim of our study is to describe the experience with RDD to cytostatics in patients being treated for gynaecological cancer in a tertiary hospital, over a period of 5 years. In this paper, we review 22 cases and 107 episodes of RDD; 86.3% of patients had advanced disease and the mortality rate at the time of data collection was 50.0%. RDD was performed on 81.8% patients for platinum, 13.6% for tax...
Source: European Annals of Allergy and Clinical Immunology - May 4, 2021 Category: Allergy & Immunology Authors: I A Coutinho F Costa Sousa F Cunha C Frutuoso C Ribeiro C Loureiro F Águas A Todo Bom Source Type: research
Analysis of the Treatment and Survival of Sinonasal Extramedullary Plasmacytoma
CONCLUSION: In patients with SN-EMP five-year overall survival was found to be 74.0% with decreased survival associated with a frontal sinus primary site and being aged 60 or older. Patients receiving no treatment, chemotherapy alone, or radiotherapy with chemotherapy was associated with lower survival. Receiving surgery plus radiotherapy was associated with the highest five-year overall survival.PMID:35440217 | DOI:10.1177/19458924221092529
Source: American Journal of Rhinology and Allergy - April 20, 2022 Category: ENT & OMF Authors: Jeff Gao Christopher C Tseng Gregory L Barinsky Christina H Fang Jordon G Grube Wayne D Hsueh Soly Baredes Jean Anderson Eloy Source Type: research
Mesna, an unusual agent causing hypersensitivity reactions during chemotherapy
Ann Allergy Asthma Immunol. 2022 Apr 25:S1081-1206(22)00364-7. doi: 10.1016/j.anai.2022.04.023. Online ahead of print.NO ABSTRACTPMID:35476968 | DOI:10.1016/j.anai.2022.04.023
Source: Annals of Allergy, Asthma and Immunology - April 27, 2022 Category: Allergy & Immunology Authors: Elizabeth Mu ñoz-Osores Ang élica Wietstruck Rodrigo Hoyos-Bachiloglu Source Type: research
Analysis of the Treatment and Survival of Sinonasal Extramedullary Plasmacytoma
CONCLUSION: In patients with SN-EMP five-year overall survival was found to be 74.0% with decreased survival associated with a frontal sinus primary site and being aged 60 or older. Patients receiving no treatment, chemotherapy alone, or radiotherapy with chemotherapy was associated with lower survival. Receiving surgery plus radiotherapy was associated with the highest five-year overall survival.PMID:35440217 | DOI:10.1177/19458924221092529
Source: American Journal of Rhinology and Allergy - April 20, 2022 Category: ENT & OMF Authors: Jeff Gao Christopher C Tseng Gregory L Barinsky Christina H Fang Jordon G Grube Wayne D Hsueh Soly Baredes Jean Anderson Eloy Source Type: research
Mesna, an unusual agent causing hypersensitivity reactions during chemotherapy
Ann Allergy Asthma Immunol. 2022 Apr 25:S1081-1206(22)00364-7. doi: 10.1016/j.anai.2022.04.023. Online ahead of print.NO ABSTRACTPMID:35476968 | DOI:10.1016/j.anai.2022.04.023
Source: Annals of Allergy, Asthma and Immunology - April 27, 2022 Category: Allergy & Immunology Authors: Elizabeth Mu ñoz-Osores Ang élica Wietstruck Rodrigo Hoyos-Bachiloglu Source Type: research
Analysis of the Treatment and Survival of Sinonasal Extramedullary Plasmacytoma
CONCLUSION: In patients with SN-EMP five-year overall survival was found to be 74.0% with decreased survival associated with a frontal sinus primary site and being aged 60 or older. Patients receiving no treatment, chemotherapy alone, or radiotherapy with chemotherapy was associated with lower survival. Receiving surgery plus radiotherapy was associated with the highest five-year overall survival.PMID:35440217 | DOI:10.1177/19458924221092529
Source: American Journal of Rhinology and Allergy - April 20, 2022 Category: ENT & OMF Authors: Jeff Gao Christopher C Tseng Gregory L Barinsky Christina H Fang Jordon G Grube Wayne D Hsueh Soly Baredes Jean Anderson Eloy Source Type: research
Mesna, an unusual agent causing hypersensitivity reactions during chemotherapy
Ann Allergy Asthma Immunol. 2022 Apr 25:S1081-1206(22)00364-7. doi: 10.1016/j.anai.2022.04.023. Online ahead of print.NO ABSTRACTPMID:35476968 | DOI:10.1016/j.anai.2022.04.023
Source: Annals of Allergy, Asthma and Immunology - April 27, 2022 Category: Allergy & Immunology Authors: Elizabeth Mu ñoz-Osores Ang élica Wietstruck Rodrigo Hoyos-Bachiloglu Source Type: research
Analysis of the Treatment and Survival of Sinonasal Extramedullary Plasmacytoma
CONCLUSION: In patients with SN-EMP five-year overall survival was found to be 74.0% with decreased survival associated with a frontal sinus primary site and being aged 60 or older. Patients receiving no treatment, chemotherapy alone, or radiotherapy with chemotherapy was associated with lower survival. Receiving surgery plus radiotherapy was associated with the highest five-year overall survival.PMID:35440217 | DOI:10.1177/19458924221092529
Source: American Journal of Rhinology and Allergy - April 20, 2022 Category: ENT & OMF Authors: Jeff Gao Christopher C Tseng Gregory L Barinsky Christina H Fang Jordon G Grube Wayne D Hsueh Soly Baredes Jean Anderson Eloy Source Type: research
